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We herein report on an unusual instance of non–small-cell lung carcinoma (NSCLC) with double squamous/basal-
like and glandular differentiation within the same individual 
tumor cells as documented in a biopsy sample by means of 
immunohistochemistry (IHC), electron microscopy (EM), 
and molecular investigation. Coexistence of glandular and 
squamous traits within the same tumor cells has previously 
been described in NSCLC using EM1 to testify the possibility 
of “amphicrine” biphenotypic tumors as an extreme conse-
quence of intratumor heterogeneity in lung cancer. Currently, 
ΔNp63/p40 (henceforth simply p40) is thought to be the 
most specific forerunner of squamous differentiation in the 
lung,2–4 thereby supporting the use of a minimalist IHC panel 
approach encompassing thyroid transcription factor-1 (TTF1) 
in the diagnostic workflow of demanding NSCLC cases. 
However, there is very little experience on NSCLC simultane-
ously positive for both p40 and TTF1 IHC at the level of the 
same individual tumor cells.
A 77-year-old man, former smoker (pack-year 40) was 
admitted to hospital for an 8.5-sized left hilar tumor mass 
involving major bronchi and associated with ipsilateral pleu-
ral effusion. Bronchial biopsy showed a high-grade NSCLC 
with just focal hints to squamous differentiation (Fig. 1A 
and B). Because of demanding structure, p40 (clone BC28, 
Biocare Medical, Concord, CA) and TTF1 (clone 8G7G3/1, 
Dakopatts, Glostrup, Denmark) IHC was undertaken, with 
widespread and strong decoration being unexpectedly 
observed for both biomarkers at the level of the same individ-
ual tumor cells (Fig. 1C and D). A final diagnosis of NSCLC 
with adenosquamous immunophenotype was thus rendered, 
with a comment on the possibility of facing with adenosqua-
mous carcinoma (ADSQC) and a recommendation to study 
the tumor molecularly. To further unravel such an unusual 
case, an EM study was carried out on two cylindrical tissue 
cores as small as 1 mm in diameter retrieved from the original 
paraffin block by using microarray technology, analyzing sev-
eral ultrastructural fields for consistency. EM revealed extra-
cellular lumen formation with microvilli-like cytoplasmic 
protrusions and mucous granules along with abundant peri-
nuclear tonofilaments consistent with both adenocarcinoma 
and squamous cell carcinoma differentiation at the level of 
the same individual tumor cells, respectively (Fig. 1E and F).
Molecular investigation was carried out by using the 
50-gene Ion AmpliSeq Cancer Hotspot Panel v2 approach 
with the Ion-Torrent Personal Genome Machine platform 
(both from Life Technologies, Foster City, CA) and fluores-
cence in situ hybridization analysis for FGFR1. Mutations of 
KRAS and TP53 were documented in 32% and 71% allelic 
DNA, respectively (Fig. 2A and B) and FGFR1 gene amplifi-
cation with an average copy number of 7.1 signals in all tumor 
cells (Fig. 2C), all consistent with molecular traits of either 
adenocarcinoma or squamous cell carcinoma. Because of the 
lack of EGFR mutation and the clinical presentation, neoad-
juvant chemotherapy was planned but the patient’s conditions 
rapidly worsened because of respiratory failure until death a 
month and a half after the first hospitalization.
This is the first instance, to the best of our knowledge, 
which documents by means of IHC, EM, and molecular assays 
that TTF1 and p40 coexpression at the level of the same indi-
vidual NSCLC cells underpinned concurrent bipartite squa-
mous/basal-like and glandular differentiation, probably as 
expression of stem/progenitor cells plasticity or microenviron-
mental influences. On the one hand, these findings reinforce 
the diagnostic validity of the axiom “no p40, no squamous.”3 
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FIGURE 1.  Biopsy tissue fragments 
showing poorly differentiated non–
small-cell lung carcinoma (NSCLC) 
(A,B) with focal features suggestive 
of squamous cell differentiation 
(B, insets). Upon immunohisto-
chemistry, a widespread and strong 
nuclear decoration was seen for both 
p40 (C, inset) and thyroid transcrip-
tion factor-1 (TTF1) (D, inset), sup-
porting a biphenotypic tumor at the 
level of the same individual tumor 
cells. Electron microscopy confirmed 
this dual concurrent differentiation at 
the level of the same individual cells 
showing (E) tumor cells partly lining 
lumen spaces with cytoplasm exten-
sions (arrowhead), numerous mucous 
granules (asterisks) and abundant 
electron-dense thick tonofilaments 
around the nucleus (arrows), and 
(F) tumor cells with adjacent lumen 
(arrowhead) and bundles of electron-
dense tonofilaments (arrows).
On the other hand, they challenge the notion that, if a case 
is positive for an adenocarcinoma marker such as TTF-1, the 
tumor should be tautologically classified as NSCLC favor 
adenocarcinoma, regardless of the concurrent expression for 
squamous markers.5 As a matter of fact it could be argued that 
whether it was more appropriate the term NSCLC favor ade-
nocarcinoma as recommended by current guidelines5 or rather 
NSCLC favor ADSQC on the basis of this intriguing double 
lineage at the level of the same individual cells, although an 
ultimate diagnosis of ADSQC would be only suggested in 
biopsy samples,5 as we really rendered in our pathology report. 
As some uncertainty still exists in the treatment of ADSQC, it 
is important for the pathologists to be aware of these challeng-
ing biomarker combinations (we observed a few other simi-
lar instances in either biopsy samples or surgical specimens). 
Therefore, we support the term ADSQC or, at least, NSCLC 
with adenosquamous immunophenotype for better witnessing 
about such an “amphicrine” biphenotypic tumor.
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FIGURE 2.  Mutations of KRAS 
(AAA>AAT, K117N, exon 4, 
32% allelic DNA) (A) and TP53 
(GTG>GGG, V272G, exon 8, 71% 
allelic DNA) (B) gene are shown as 
derived from targeted next genera-
tion sequencing, which are either 
typical of or frequent in lung adeno-
carcinoma. Tumor cells showed also 
concurrent FGFR1 gene amplification 
typical of squamous cell carcinoma, 
with an average copy number being 
7.1 signals in all tumor cells (C, inset).
